BPC-157 vs TB-500: How the Two Repair Peptides Differ.

BPC-157 and TB-500 are two different research peptides studied in two different pathways. BPC-157 is a 15-amino-acid synthetic fragment of a gastric juice protein, studied mainly for angiogenesis and nitric oxide signaling. TB-500 is a 7-amino-acid synthetic fragment of thymosin beta-4, studied for actin binding and cell migration. They are not two versions of the same thing, which is exactly why research blends pair them. Everything below is drawn from published cell-culture and rodent work, and every material referenced is for in vitro research use only.

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide: a chain of 15 amino acids whose sequence corresponds to a partial sequence of a protein identified in human gastric juice. In the literature it is called the stable gastric pentadecapeptide BPC 157, and the "stable" refers to its reported resistance to breakdown in gastric juice, a low-pH environment where most peptides degrade quickly. It was characterized by Sikiric, Seiwerth and colleagues at the University of Zagreb, whose group has authored the bulk of the foundational animal work over three decades (Sikiric et al., 2014). The name appears in the literature as BPC 157, Body Protection Compound 157, and PL 14736. It is a research chemical, not an ingredient in any approved drug, and it is not approved by the FDA. For a fuller account of the compound on its own, see the BPC-157 research overview.

What is TB-500?

TB-500 is a synthetic peptide corresponding to the actin-binding region of thymosin beta-4, a 43-amino-acid protein present in nearly all mammalian cells. Thymosin beta-4 is described by Goldstein, Hannappel and Kleinman (2005) as the major actin-sequestering molecule in eukaryotic cells (Goldstein et al., 2005). The fragment sold as TB-500 covers residues 17 to 23 of the parent protein, sequence LKKTETQ, which contains the conserved LKKTET hexapeptide that biochemical studies identify as the main contact site with actin (Vancompernolle et al., 1992; Simenel et al., 2000). In the literature the segment is usually written as thymosin beta-4 fragment 17-23 or the Tβ4 actin-binding peptide; "TB-500" is a vendor name, not a name you will find on PubMed. Like BPC-157, it is not approved by the FDA.

What mechanisms have been studied for BPC-157?

The most cited mechanism is receptor-level modulation of angiogenesis. Hsieh and colleagues (2017) reported that BPC-157 increased mRNA and protein expression of VEGFR2, but not of VEGF-A itself, in cultured human vascular endothelial cells, and that it activated the VEGFR2-Akt-eNOS signaling pathway. The effect depended on receptor internalization: the endocytosis inhibitor dynasore suppressed it. In the same paper the peptide increased vessel density in a chick chorioallantoic membrane assay and accelerated the return of blood flow in a rat hind-limb ischemia model (Hsieh et al., 2017). A second line of work looked at connective tissue cells. Chang and colleagues (2014) exposed rat Achilles tendon fibroblasts to BPC-157 in culture and found the growth hormone receptor among the most upregulated genes, with expression rising at both mRNA and protein level and Janus kinase 2 activated downstream (Chang et al., 2014). The nitric oxide link runs through both: Sikiric and colleagues (2014) summarize BPC-157's interaction with the NO system across rodent models, including the counteraction of the NO-synthase blocker L-NAME (Sikiric et al., 2014). Every one of these findings comes from cell culture or animals. Published human data is limited to a few small reports and no regulatory body has approved the compound.

What mechanisms have been studied for thymosin beta-4 and TB-500?

The core mechanism is G-actin sequestration. Thymosin beta-4 binds monomeric (G-) actin and holds it out of the polymer pool, which in turn regulates how much filamentous (F-) actin a cell can assemble. Vancompernolle and colleagues (1992) showed that a single amino-acid substitution inside the LKKTET motif flips the protein from a sequestering to a polymer-modulating molecule, marking the hexapeptide as the working part (Vancompernolle et al., 1992). Rossenu and colleagues (2003) later mapped which residues in the motif matter most for actin affinity. Sosne, Qiu, Goldstein and Wheater (2010) tested short synthetic segments of thymosin beta-4 in cell culture and reported that the region containing LKKTETQ was the segment associated with cell migration and endothelial tube formation, while different regions carried different activities (Sosne et al., 2010). That paper is the reason TB-500 is defined as residues 17 to 23 and not as the whole protein.

One point matters when reading thymosin beta-4 papers against TB-500. The parent protein is broken down in tissue into a separate N-terminal tetrapeptide, Ac-SDKP, and Myöhänen and colleagues (2011) showed that prolyl oligopeptidase releases Ac-SDKP from thymosin beta-4 and that this release drives an angiogenic response in vitro and in vivo (Myöhänen et al., 2011). Ac-SDKP is residues 1 to 4. TB-500 is residues 17 to 23. Findings about Ac-SDKP therefore describe the full protein, not the fragment, and a study of the whole 43-residue molecule is not a study of TB-500. As with BPC-157, all of this evidence is preclinical: purified actin assays, cultured cells and rodent models.

How do BPC-157 and TB-500 compare side by side?

Dimension	BPC-157	TB-500
Amino-acid length	15 (pentadecapeptide)	7 (heptapeptide, LKKTETQ)
Origin protein	Partial sequence of a human gastric juice protein	Thymosin beta-4, residues 17 to 23 of a 43-residue protein
Studied pathway	VEGFR2 upregulation, Akt-eNOS nitric oxide signaling, growth hormone receptor expression	G-actin sequestration, actin polymerization, cell migration
Typical research model	Rat models, chick chorioallantoic membrane, cultured endothelial cells and tendon fibroblasts	Purified actin binding assays, cultured cells, rodent models of the parent protein
Published human clinical data	Limited to a few small reports; not FDA approved	None located for the 17-23 fragment; not FDA approved
What the NLL certificate reports	Supplied together as the Wolverine Stack blend: HPLC purity and LC-MS identity per lot, published on the lab reports page

Why are BPC-157 and TB-500 studied together?

Because they read out different pathways in the same tissue model. A laboratory studying angiogenesis and extracellular matrix remodeling can run a VEGFR2 or nitric oxide endpoint against BPC-157 and an actin or cell-migration endpoint against TB-500 in one preparation, which is the logic behind a two-compound research blend. Next Level Labs lists this blend as the Wolverine Stack in the tissue repair research category, alongside the single compounds. The current lot, PS07-BCTB20, was tested by ILS Laboratories and its published certificate of analysis reports 99.94% purity by HPLC, dated August 14, 2026. That figure is drawn from the signed COA in the lab reports library, not from a marketing summary, and a guide to reading the certificate itself is in how to read a peptide COA. Note what a certificate does and does not establish: it reports identity and purity of the material in the vial. It says nothing about biological activity.

Which pathway is each compound studied in?

The "which is better" search has no research answer, so the useful question is which pathway a model is built to measure. If the endpoint is receptor expression, endothelial tube formation, or nitric oxide synthase activity, the literature on BPC-157 applies. If the endpoint is actin polymerization, cytoskeletal dynamics, or cell migration in a scratch or transwell assay, the thymosin beta-4 fragment literature applies. Neither compound has been studied head to head against the other in a published trial, and no human clinical data supports ranking them. A laboratory chooses the compound for the pathway, or the blend for both, and reads the result against the preclinical record described above.

Frequently asked questions

What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-amino-acid synthetic fragment of a protein found in gastric juice, studied in rodent models and cell culture for VEGFR2 upregulation and nitric oxide signaling. TB-500 is a 7-amino-acid synthetic fragment of thymosin beta-4 (residues 17 to 23, LKKTETQ), studied for G-actin binding and cell migration. Different origin proteins, different pathways.

What is the BPC-157 and TB-500 blend?

A research blend that supplies both peptides in one vial so a laboratory can study the angiogenesis pathway and the actin-binding pathway in the same model. At Next Level Labs the blend is listed as the Wolverine Stack, and its current lot carries a published third-party certificate reporting HPLC purity. It is for in vitro research use only.

Is BPC-157 or TB-500 approved by the FDA?

No. Neither BPC-157 nor TB-500 is approved by the FDA for any use, and neither is an ingredient in any approved drug. The published evidence for both is preclinical: purified protein assays, cell culture, and rodent models. Research suppliers offer them strictly as laboratory reference materials, not for human consumption.

Which is better, BPC-157 or TB-500?

The question has no research answer, because the two compounds are studied in different pathways rather than against each other. BPC-157 studies measure VEGFR2 and nitric oxide endpoints. TB-500 studies measure actin binding and cell migration. A laboratory picks the compound whose pathway its model is designed to read out, or a blend to study both.

For in vitro research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any condition. This article summarizes published research and is not medical advice.